Amarin Corp Plc (AMRN)

[Atom0aks]

Atom - My bet is that they get exactly the population that R-It included:
1) Existing CVD, on statins, with TGs>150 (or 135)
2) T2DM, on statins, with CV risk, and TGs>150 (or 135)

There are no data to support a broad primary prevention label (R-It did not include any non-diabetic primary prevention), so this would be highly unlikely.

A label less than R-It ignores a solid statistical argument for including both, and in the end, I think the scientists and statisticians will agree on this.

I completely agree, but I think the diabetes indication is throwing a huge monkey wrench in the process based on what we saw happen to ezetimibe.

Who knows, maybe I'm wrong, and the briefing docs show the question is completely different :/